| Name | Title | Contact Details |
|---|
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.
Infomed is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Nizhoni Health, we believe that quality of care and quality of staff go hand-in-hand. Our highly trained staff consists of qualified, experienced nurses and clinical specialists. Our nurses have worked in a variety of clinical settings including the major teaching hospitals within the metropolitan area. Nizhoni Health is a Medicare/Medicaid certified home health agency. Our enduring goal is to provide an effective alternative to inpatient hospitalization and assist clients in making the transition to the community. All clients are treated with dignity and respect.
Antibody Solutions is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWounds first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Companys lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWounds pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com